Now enrolling ...

Hepatitis C Virus

• Study to evaluate the effectiveness, tolerability and safety of combination doses of an investigational oral drug with Ritonavir and with or without Ribavirin.  Patients in this study will not be treated with pegylated Interferon.  Patients with no prior exposure to treatment or patients who did not respond to previous treatment may qualify. 

Ulcerative Colitis (UC)/Crohn's Disease

• Study for patients with moderate to severe Crohn's that tests the effectiveness of an investigational drug in patients who have previously failed at least one other therapy.  If you qualify for this study you will be randomized to receive study drug or placebo infusions.   
• Study to compare the effectiveness of Infliximab (Remicade) versus placebo in preventing relapse of CD after ileocolonic resection.  Infliximab has been approved by the FDA in the treatment of CD.  The use of infliximab for the prevention of relapse is considered investigational.  To qualify patients must have undergone resection within 24 days of study treatment.
• Study to assess the safety and tolerability of single subcutaneous (SC) doses of study drug in subjects with mild to moderate ulcerative colitis (UC). 

Barrett’s Esophagus 

• Barrett’s esophagus is evaluated via endoscopy by physician’s with additional training of esophageal anatomy to see if Barrett’s diagnosis can be reversed.

Infant GERD

• Study for infants age 1 to 11 months for the treatment of GERD.  Subjects will receive multiple doses of rabeprazole (ACIPHEX), currently marketed for short term use in adults.

Updated August 2011

For more information or eligibility criteria, call our Research Hotline number at 612-870-5599, OR email the following information and we will follow up with you to discuss your interest: